I'm no expert on these things, but the Dutch company Uniqure has just done a deal with CSL-Bering in which the latter will provide the money upfront for the completion of Uniqure's clinical studies of their hemophilia B gene therapy. Once the studies are completed, and assuming the results are positive, CSL-Bering will then take over the manufacture, marketing, and sales, and the two companies will share the profits. This did not involve any dilution of the shares. Could a simlar model be used between RVX and BP?